life scienc tool diagnost initi
bottom line lead global manufactur distributor scientif equip
consum servic use pharma biotech diagnost healthcar compani
academ government organ well industri compani highli
lever healthi industri fundament well driver rise biopharma demand
increas exposur faster-grow servic market
geograph expans improv oper effici support
organ revenu growth bp underli margin expans annual also
expect tmo role lead consolid continu highli fragment life
scienc industri success complet seven billion deal past
decad albeit futur embed forecast offer upsid
rev revenu growth expand exposur faster grow sub-
segment includ biopharma organ invest acquisit
affymetrix fei biopharma end-market repres
sale vs specif within biopharma invest
area market growth contract develop manufactur
sinc post organ growth lab product servic segment
vs perpetu innov engin continu focu
geograph expans high-growth market custom penetr
averag vs top custom also support growth longer term view
share price near perfect valuat reflect invest strength
share vs current trade ev/ebitda
multipl well histor average life scienc peer average
believ share adequ reflect robust organ growth
strengthen margin profil upsid current valuat level limit
impress beat expect ep basi time sinc
demonstr abil manag street view downsid risk greater
inevit higher expect target price base
ev/ebitda price-to-earnings still premium broader peer group suggest
limit near term upsid potenti risk includ macro spend dynam
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
mariu zoican univers toronto rotman school manag januari
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
thermo fisher lead provid instrument reagent
consum softwar servic custom span
biopharmaceut diagnost academic/government
blue sky scenario predic organ growth
upper end current lt target faster margin expans
thereon support oper leverag ppi initi
share grey sky scenario predic organ growth
lower end current lt target predic slow
fund growth stringent regulatori environ particularli
custom consolid continu compound potenti slower
expect margin expans thereon
 close
mariu zoican univers toronto rotman school manag januari
tabl content
laboratori product servic sale
life scienc solut sale
analyt instrument sale
specialti diagnost sale
geograph expans focu market
earn outlook financi resourc
mariu zoican univers toronto rotman school manag januari
figur revenu mix end market ltm
figur increas revenu exposur high growth end-
market geographi
compani data credit suiss adjust equal ttm adjust net
incom exclud net interest expens net tax benefit therefrom divid
product revenu recur biotechpharma mariu zoican univers toronto rotman school manag januari
segmentrevenueadjust oper marginsub-seg revenu total revenu detailsproduct groupsresearch safeti market channel million product extern supplier along proprietari product go market print digit contentpharma servic manufactur clinic trial servic small larg molecul pharmaceuticalslaboratori product chemic rang chemic solvent reagent use across research drug discoveri develop manufacturingbiosci reagent instrument consum custom across research life scienc appliact share marketgenet scienc instrument incl pcr technolog reagent use provid genom solut share marketbioproduct upstream cell cultur media downstream purif analyt detect quantif process impur single-us product market chromatographi mass spectrometri chromatographi lc ic gc element analysi mass spectrometri life scienc ms inorgan ms instrumentationmateri structur analysi electron microscop molecular spectroscopi laboratori element analysi offeringschem analysi materi miner portabl analyt environment process instrument well radiat measurementshealthcar market channel chain busi clinic diagnost offer product manufactur well third-partiesclin diagnost reagent analysi masur blood urin chemistryimmunodiagnost diagnosi monitor allergi asthma autoimmun diseasesmicrobiolog cultur media collect transport system instrument consum detect pathogen qualiti control productstranspl diagnost transplant center hospit evalu compat donor recipi pre-transplantanalyt product billionlif scienc mariu zoican univers toronto rotman school manag
initi coverag thermo fisher scientif nyse neutral rate
target price world largest provid scientif equip consum
servic use pharmaceut biotech compani hospit clinic diagnost lab
well varieti set includ research industri qualiti assur
government applic serv custom support employe
across countri gener estim billion revenu report
genesi stand today stem merger legaci thermo electron
found fisher scientif found result format one
largest diversifi compani life scienc tool industri sinc merger
reli highli acquisit strategi expand breadth product servic
offer geograph footprint sinc deploy billion cash
complet acquisit notabl billion affymetrix
billion fei billion patheon billion recent
particip billion life scienc tool industri grow annual
averag despit maintain comprehens portfolio industri
command estim market share vs top three player underscor
market fragment runway share captur longer term rise healthcar cost
associ age popul grow demand treatment complex
chronic diseas underpin secular tailwind current fuel invest healthcar
servic infrastructur research global accord evaluatepharma global
pharmaceut spend expect rise billion see figur coincid
us nation healthcar expenditur increas compound-annual-growth-rate
figur structur tailwind continu drive greater demand diagnost
novel biolog therapi therebi product servic also view
benefit follow driver
biopharma growth engin maintain diversifi portfolio recent year
made signific effort increas penetr faster grow biopharma
market rise high-single-digit annual organ invest acquisit
affymetrix fei patheon tmo increas focu biopharma market
repres total sale vs inher faster end-market
help continu achiev surpass long-term organ growth goal view
importantli extens capabl allow provid comprehens end-to-end
product across biopharma workflow
perpetu innov engin industry-lead billion annual budget
manufactur revenu scientists/engin
commit deliv high-impact innov custom across
segment innov driven customer-centr focu vast scale enabl
collect inform collabor custom key opinion leader identifi
need potenti new approach sinc also reli scientif
advisori board compris scientif expert order commun import scientif
inform trend manag help keep finger industri puls
provid invalu feedback regard potenti pipelin project recent product
launch includ quantstudio real-tim pcr smart instrument voice-
activ command hand free oper life scienc solut segment
immunocap test peanut allergi specialti diagnost well sever new
acceler servic fuel growth mark entranc faster grow
annual highli fragment under-penetrated contract develop
mariu zoican univers toronto rotman school manag
manufactur organ space acquisit patheon august
billion ebitda sinc tmo busi key
growth driver lp segment post organ growth
first nine month organ growth acceler
growth respect go forward view unit
support top-line growth particularli continu expand presenc organ
inorgan top player compris market note recent
industri invest categori endors tmo effort other
seemingli follow suit
geograph expans focu high growth market also well-posit
emerg market grow presenc china ttm revenu
vs india south korea well faster grow market tmo
emerg market invest coincid rise world-wide spend industri
growth develop market outpac develop nation per oecd data
us uk japan greater emphasi improv medic care environment
condit food safeti emerg market
consist oper margin expans impress track record tmo effort
grow ep support commit drive effici expand margin via
synergi captur first introduc well-known oper effici framework ppi
sinc becom key pillar strategi long term profit
improv part drive adjust oper margin
go forward expect continu experi margin expans despit
slight downtick compani move closer long term adjust
oper margin target
alloc cash strateg return
sharehold via share buyback dividend yield highlight tmo role
consolid highli fragment life scienc industri consist driven
growth deliv valu disciplin strategi includ seven deal larger
billion past decad dynam expect continu longer term
also deliv valu sharehold return billion capit sinc
billion share buyback billion dividend dividend relat outlay grown
compound-annual-growth-rate sinc note futur share buyback current
embed assumpt repres upsid estim
price perfect valuat reflect invest strength risk share ralli
vs current trade ep
ev/ebitda multipl histor averag ebitda
overal life scienc tool diagnost peer averag ev/ebitda view
premium warrant given robust organ growth profil expand margin profil
upsid current valuat level may limit share current price near
perfect manag impress beat expect ep basi
time sinc demonstr abil success manag street view
perform also offer risk even slight miss offer meaning downsid
potenti target price base ev/ebitda price-to-earnings
still premium broader life scienc tool diagnost peer group suggest
downsid risk includ deterior macroeconom condit destabil china
neg deriv impact trade disrupt declin invest biopharmaceut
compani reduc govern fund industri consolid deal integr failur
shift regulatori environ upsid risk includ strengthen macroeconom
condit heighten fund better expect deal integr
mariu zoican univers toronto rotman school manag januari
thermo fisher scientif lead provid instrument consum servic
custom engag scientif research varieti end market rang
pharmaceut biotechnolog compani clinic diagnost laboratori academ
government research institut custom industri environment industri
innov technolog servic help custom address complex
analyt challeng advanc patient diagnost enhanc laboratori effici
compet billion life scienc tool diagnost market grow
annual despit maintain comprehens portfolio industri
command estim market share vs top three player underscor
market fragment runway share captur longer term also expect
maintain leadership posit leverag competit advantag innov scale
genesi stem merger legaci thermo electron found
fisher scientif found result format one largest
diversifi compani life scienc tool industri sinc merger acquisit
key compon growth strategi expand breadth product
servic offer geograph footprint sinc deploy billion
cash complet acquisit notabl life technolog billion
affymetrix billion fei billion patheon billion
note current servic four primari custom end market five core
brand thermo scientif appli biosystem invitrogen fisher scientif uniti lab
servic support employe across countri oper report
compani data credit suiss estim revenu adjust oper margin reflect cs
estim gener billion sale reflect organ growth
line recent increas three-year target vs prior histor
grown organ well lower end three-year target view
manag often convey conserv messag investor seek high
convict growth potenti rais investor aspir growth support
four target end-market includ revenu
segmentrevenueadjust oper marginquick take overviewproduct groupslaboratori product equip consum distribut channel serviceslif scienc consum special instrument capit equip laboratori productionspecialti consum mariu zoican univers toronto rotman school manag januari
academ govern diagnost healthcar industri appli
figur revenu mix end-market
compani data credit suiss estim period shown repres
ltm march relev year
geograph maintain lead posit north america region contribut
half overal revenu said also maintain meaning exposur intern
deriv revenu europ asia-pacif respect figur
importantli expect asia-pacif exposur percentag revenu continu
expand time region increasingli focus life scienc market dynam
explor depth page term product mix offer consum
revenu instrument servic highlight total
revenu recur natur provid meaning level visibl quarterli revenu
trend compar life scienc peer group averag maintain lower level
averag recur revenu mix figur anoth rel advantag
figur revenu mix geographi
figur revenu mix product type
compani data credit suiss base ltm revenu
compani data credit suiss base ltm revenu
 product revenu recur mariu zoican univers toronto rotman school manag januari
figur recur revenu mix across life scienc peer group
importantli report respect perform across four busi unit laboratori
product servic lp life scienc solut lss analyt instrument ai
specialti diagnost sd tmo laboratori product servic segment remain
largest segment contribut revenu sinc meaning
increas rel exposur life scienc solut segment larg due
acquisit complet februari explor greater depth
four segment particular focu evolut segment well tmo
current offer posit
figur revenu mix segment incl interseg elimin
laboratori product servic sale
estim laboratori product servic lp segment repres roughli
consolid revenu incl interseg elimin offer million
product supplier extern vendor span across varieti
laboratori set make one-stop shop custom across end market roughli
scienc solutionsanalyt instrumentsspeci diagnosticslaboratori product mariu zoican univers toronto rotman school manag januari
lp revenu recur natur revenu relat inher
lumpier instrument purchas appreci visibl recur revenu
standpoint note lp ebit margin meaning tmo consolid margin
profil dynam expect continu
expect lp sale grow compound-annual-growth-rate long term driven sustain growth
global healthcar broader life scienc invest increas complex drug
develop rise incom global continu focu effici biopharma
end market higher outsourc penetr rate cro clinic research
figur lp revenu mix product type
three busi includ research safeti market channel pharma servic
laboratori product chemic tmo lp segment offer special suppli chain
inventori manag via fisher scientif brand manufactur lab product
provid biopharma servic support clinic trial workflow label packag
distribut logist servic
figur lp revenu mix busi segment
compani data credit suiss estim base revenu
figur lp revenu mix geographi
compani data credit suiss estim base revenu
revenu total product servicestmo consolid ebit marginresearch safeti market product mariu zoican univers toronto rotman school manag
research safeti market channel major lp segment sale
deriv research safeti market channel busi serv custom across
academ pharmaceut biotechnolog govern industri end market offer
million product extern supplier includ
becton dickinson mettler toledo among other well proprietari product tmo
suppli chain busi goe market segment-relev print digit content
global network resel distributor websit www fisherscientif com
account transact channel busi vs
also provid technic suppli chain servic via customer-fac
employe on-sit stock locat
provid substanti valu custom particularli market highli
fragment suppli base vast mix product categori consum reagent chemic
instrument stringent regulatori requir tmo channel busi aim
one-stop shop scientif need across entir platform on-sit inventori
manag lab manag servic purpose-built integr suppli chain
supplier aggreg servic economi scale also highlight special channel
capabl includ depart transport dot hazard materi certifi fleet
carrier chemic inventori manag track well purpose-built distribut
center suppli chain includ lot control storag transport medic devic
biopharma product
extens reach suppli chain distribut channel larg establish
transform merger novemb combin thermo electron
billion enterpris valu predominantli analyt instrument portfolio fisher
scientif billion global suppli chain presenc acquisit relat busi
unit bolster tmo channel offer well logist suppli chain servic
pharma servic pharma servic busi cover entir spectrum
develop manufactur clinic trial servic small molecul larg
molecul pharmaceut repres lp sale specif help
develop formul activ pharmaceut ingredi biolog provid scale
manufactur capabl addit label packag distribut logist servic
drug substanc servic support develop manufactur small
molecul activ pharmaceut ingredi api biolog activ compon
product current good manufactur practic cgmp condit meanwhil drug
product servic manufactur small larg molecul product offer breadth
dosag form special capabl oral solid steril dosag form well
scientif expertis solut lastli clinic trial servic provid compani
special packag over-encapsul multi-lingu special label phase
phase iv clinic trial specialti pharmaceut logist clinic supply-chain
plan manag
remind made grand entri contract develop manufactur
market key compon pharma servic unit acquisit patheon lead
contract develop manufactur organ august billion
ebitda patheon offer comprehens rang activ pharmaceut
ingredi api finish drug product servic across small larg molecul product
includ formul develop clinic commercial-scal manufactur packag
life cycl manag uniqu end-to-end offer allow custom partner
singl outsourc provid throughout clinic develop phase commerci
mariu zoican univers toronto rotman school manag januari
figur patheon revenu mix servic
expect continu build lead posit intern invest
 expand patheon st loui plant million invest
expans st loui plant largest outsourc single-us biolog site
north america addit march announc spend million increas
capac steril liquid lyophil freeze-dri product develop commerci
manufactur greenvil north carolina site well two addit site itali
term inorgan invest busi acquir brammer lead
viral vector billion ntm sale may brammer viral vector capabl
support pharma biotech compani conduct clinic trial gene cell therapi
key emerg growth area drug develop cours year brammer
execut project gene therapi clinic trial commerci process
importantli brammer expect gener million annual revenu
bp top-line growth gene therapi market grow
medium-term provid exposur faster grow section alreadi high growth
biopharma market also note purchas glaxosmithklin cork site facil
oper uk million may provid greater api develop
manufactur capac capabl intern
figur tmo recent invest
drug product servic finish dosag manufactur substanc servic api manufactur develop servic datedetailsacquisit lead previouli publicli list pthn legaci patheon organ growth acceler msd hsd part repres entri arena acquisit brammer viral vector manufactur market grow annual brammer track gener revenu steril inject ad capac steril liquid freez dri product develop commerci manufactur specif expans includ two site itali one carolina acquisit gsk facil ireland gain access highli special api potenti treat childhood cancer depress parkinson expand capac facil previous underutil st loui facil april expand st loui biolog facil legaci patheon facil site largest outsourc single-us biolog site north mariu zoican univers toronto rotman school manag januari
aforement intern invest intern inorgan busi
weigh margin near term pharma servic busi repres inher
higher margin busi compar busi broader lp segment prior
acquisit patheon post oper margin ltm april well
ahead lpss oper margin histor averag longer
term pharma servic busi drive margin expans becom larger
proport overal revenu segment albeit like still consolid compani
laboratori chemic repres lp revenu laboratori chemic
busi unit offer broad rang chemic solvent reagent use across varieti
applic includ research drug discoveri develop manufactur
specif tmo portfolio includ organ chemic use synthes new materi
bioreag use variou applic cell growth detail protein analysi high-pur
analyt reagent novel chemic build block reactiv intermedi screen
librari use acceler drug discoveri well preciou metal salt solut
busi unit also support sampl prepar storag well offer centrifug
cold storag liquid handl
life scienc solut sale
estim life scienc solut lss segment gener billion revenu
repres roughli consolid revenu incl elimin larg serv
pharmaceut biotechnolog agricultur clinic academ
government end market offer reagent instrument consum use
biolog medic research lss highli lever recur revenu sale
larg repres consum product margin well consolid
expect lss sale grow compound-annual-growth-rate long term leverag lead
scale servic offer take advantag grow global demand biolog
therapeut adopt genet analysi clinic applic rise government
healthcar invest precis medicin emerg market includ throughout apac
name china korea india
histor context form lss segment conjunct
billion acquisit life technolog ntm sale deal close februari ad
roughli billion revenu increment revenu recur
scienc solutionsconsolid ebit mariu zoican univers toronto rotman school manag januari
natur consumables/servic bidder includ roch
numer privat equiti firm note life technolog origin merger
invitrogen appli biosystem previous appli biosystem
stand-alone publicli trade compani focus technolog use dna rna protein
small molecul analysi like today invitrogen activ acquisit front
ad nine life scienc compani portfolio
life technolog significantli expand tmo presenc genom offer
chromatographi cell biolog dna test appli market offer
forens anim health food safeti test life technolog also ad
employe product patent tmo portfolio brand gain
acquisit includ invitrogen ion torrent gibco appli biosystem
figur life organ growth prior merger
organ growth exclud impact acquisit foreign exchang
follow acquisit life technolog reseg busi
introduc lss segment renam analyt technolog segment analyt
instrument hous major life technolog asset lss
segment includ tmo legaci bioscienc asset previous includ
analyt technolog segment tmo global chemic busi move
analyt technolog laboratori product servic segment meanwhil two
smaller busi move specialti diagnost segment
time bolster lss segment seri addit meaning
advanc scientif februari acquir advanc scientif
million ltm sale strengthen bioproduct busi custom
single-us technolog bioequip offer
affymetrix march close billion acquisit affymetrix
ltm sale public trade compani focus cellular genet analysi
particularli reproduct health agricultur bioscienc compani also offer
antibodi assay flow cytometri single-cel biolog applic note
affymetrix revenu consum servic time acquisit
strengthen overal segment recur revenu mix
integenx march close acquisit integenx supplier
product use genet analysi forens law enforc applic
million ltm sale integenx ad roughli million annual sale
appli biosystem -- rebrand life technologiesconsum servic mariu zoican univers toronto rotman school manag januari
acquir bd advanc bioprocess busi unit global provid cell cultur
supplement increas yield reduc variabl product biolog
million ltm sale complement cell cultur single-us technolog
tmo watch lss segment improv consist low-single-digit growth
mid-single-digit organ sale growth lss segment also recent post six
consecut quarter high-single-digit organ revenu growth greater
specif asset acquir busi benefit leverag
tmo commerci footprint ppi initi cost synergi supplement
reinvest cost save help drive innov
current tmo lss segment compris three busi unit bioproduct bioscienc
genet scienc explor greater detail also highlight tmo
geograph mix segment revenu deriv apac region market
compani continu emphas growth opportun
figur lss revenu busi mix
figur lss revenu mix geographi
organ growth lss current mariu zoican univers toronto rotman school manag
bioscienc tmo bioscienc unit play billion market current
maintain roughli share repres meaning runway growth tmo bioscienc
busi provid reagent instrument consum custom across variou
research life scienc applic support effort discov new drug vaccin
well diagnos diseas certain case tmo vast bioscienc portfolio includ product
reagent instrument consum protein biolog molecular biolog sampl
prepar cell imag analysi tool use genet engin amplif
quantif analysi cell cultur media reagent plastic preserv grow
mammalian cell fluorescence-bas technolog protein analysi product figur
notabl brand includ invitrogen reagent gibco cell cultur evo cell imag
acquir part aforement transact
tmo bioscienc strategi center high-impact innov capabl enhanc
commerci approach expand capabl bioscienc space bolt-on
acquisit strengthen portfolio includ ebiosci aforement
acquisit affymetrix also leverag scale channel strength drive share
gain above-market growth bioscienc market term high-impact innov
invest high-growth segment includ cell biolog repres
billion opportun grow mid-single-digit rang well molecular biolog gene
exampl may announc collabor scinogi specialist close
autom manufactur system cell therapi order develop instrument
reagent system improv product scalabl cell gene therapi
collabor scinogi develop gibco rotea counterflow centrifug
close cell process system design wash separ concentr
cell therapi sampl launch intern societi cellular therapi
meet melbourn australia may
genet scienc clinic next-gen sequenc tmo genet analysi unit play
billion market current maintain roughli share unit support
custom research clinic appli market variou instrument relat
reagent use provid genom solut sell polymeras chain reaction pcr technolog
use dna analysi genet analyz use commerci clinic research
applic also market clinic next-gen sequenc technolog target dna
bioscienc products- reagent instrument consum use protein biolog molecular biolog sampl prepar cell imag analysis- antibodi product protein purif detect modif analysis- sequenc detect purif product use high content analysi nucleic acids- mani offer also use appli market includ agricultur forens diagnost product develop toxicolog research tool use genet egin amplif quantif analysi rna isol includ stem cell reprogram kit transfect reagent rna interfer reagents- gene edit tool gene synthesi products- cell cultur media reagent plastic preserv grow mammalian cells- fluorescence-bas technolog facilit label molecul biolog research drug discoveri cell analysi instrument includ flow cytomet imag platform enabl fluoresc microscropy- protein analysi includ pre-cast electrophoresi gel separ nucleaic acid protein western blot stain mariu zoican univers toronto rotman school manag januari
sequenc solut use research oncolog applic offer microarray
technolog use gene express genotyp reproduct health brand includ
appli biosystem pcr real-tim pcr ion torrent axiom microarray
former two obtain via acquisit latter via acquisit
affymetrix
figur brand tmo genet scienc clinic next-gen sequenc
within genet analysi unit emphas clinic next-gen sequenc
key growth driver market grow mid-teen rang custom seek
effici afford technolog determin statu clinic action gene
focu also acceler research therapi select current illumina
domin market share note establish foothold
market second largest player runway grow support market growth
potenti share gain smaller player market
figur market share consolid revenu
bioproduct tmo bioproduct busi play billion market grow
double-digit rang driven growth biolog emerg biosimilar focu
immunotherapi tmo bioproduct busi sell portfolio product solut
meet need develop manufactur biolog therapeut vaccin
busi offer servic solut upstream cell cultur media
downstream purif analyt detect quantif process/product impur
varieti single-us product across biolog workflow relat servic help
custom optim product platform
appli biosystems torrentaxiom pcr real-tim pcr sequenc microarray omic omic mariu zoican univers toronto rotman school manag januari
broadli maintain lead posit upstream process note recent
activ around downstream process creat materi impact refer
bioproduct workflow compris four basic workflow function includ cell cultur
filtrat purif
upstream process well
upstream capabl lead posit capabl includ cell
cultur media single-us technolog analyt detect quantifi impur
relat servic optim product enabl faster setup turnaround time
minim valid requir larg up-front capit outlay
downstream capabl provid chromatographi rapid molecular product
well solut enabl scalabl manufactur cell therapi base drug note
maintain rel smaller posit downstream market view
continu gain share chromatographi
go forward expect continu invest busi focus
strengthen posit across bioprocess workflow sinc highlight figur
note state interest expand biolog network meet grow
demand support high-single-growth unit longer term
figur continu invest bioproduct busi
analyt instrument sale
instrument capit equip laboratori product
expect ai segment repres roughli consolid
revenu offer wide rang instrument servic consum softwar
organ inorgan scientif analysi ai segment serv custom
pharmaceut biotechnolog academ government environment clinic laboratori
market among other roughli ai revenu recur natur vast
major sale deriv instruments/capit equip
expect ai sale grow compound-annual-growth-rate long term driven continu demand
tmo chromatograph mass spectromet electron microscop spectroscop
technolog potenti increment upsid stem pickup industri end
market segment ebitda margin consolid
compani averag greater capit equip exposur improv margin
bp annual averag last five year organ volum
flow product improv
invest capac expans uk manufactur single-us bioprocess containers- invest capit rapid growth biolog china shanghai bioprocess design center lead posit cell cultur media single-us technolog expand single-us offer via acquisit advanc scientifics- acquir control system softwar via finess solut revenu integr exist capabl product chemic single-us storag acquir advanc bioprocess mariu zoican univers toronto rotman school manag januari
figur ai revenu product type
ai divers geograph exposur lever high-growth market
segment revenu stem apac/row ai made notabl invest apac
includ manufactur center excel singapor engin emerg digit
technolog center india china innov center china manufactur center
importantli segment span three primari busi includ chromatography/mass
spectrometri chemic analysi materi structur analysi explain
detail three busi experienc greater organ revenu
growth
figur ai revenu busi mix
figur ai revenu geograph mix
chromatographi mass spectrometri tmo chromatographi mass spectrometri
busi provid instrument custom across appli technolog life scienc
research market support organ inorgan analysi importantli complement
chromatographi mass spectrometri equip offer rang consum
inform data system sampl prepar product support equip util
relat chromatographi market tmo posit evolv meaning sinc
nich player high-pressur liquid chromatographi hplc ga
chromatographi gc complet acquisit dionex billion
ltm sale third largest chromatographi compani global enhanc tmo
instrumentsconsolid ebit marginchromatographi mass structur mariu zoican univers toronto rotman school manag januari
posit environment water test via dionex ion liquid chromatographi
portfolio dionex acquisit also ad chromeleon lead chromatographi
data manag softwar offer integr samplemanag lab
inform manag lim follow year invest heavili
innov technolog across liquid ga ion chromatographi leverag mass
spectrometri leadership custom relationship drive growth today lead
player chromatographi market comprehens portfolio detail figur
tmo chromatographi busi evolv low growth busi high-
remind chromatographi techniqu use separ identifi quantifi chemic
compon substanc base compon physic and/or chemic trait tmo
chromatographi busi offer instrument use perform liquid chromatographi ion
chromatographi ga chromatographi element analysi
environment test qualiti assur purpos food pharmaceut
scientif
also maintain lead posit mass spectrometri market remind mass
spectrometri techniqu use analyz ion base mass-to-charg ratio
discern ion ident quantiti within mixtur applic drug metabol
proteom environment analysi food safeti toxicolog clinic research highlight
tmo variou mass spectrometri offer figur
thermo fisher chromatographi product offeringsliquid chromatographi lc analyz complex sampl matrici liquid high-pressur liquid chromatographi hplc ultrahigh pressur liquid chromatographi uhplc system offer high throughput sensit sold either stand-alon system integr mass spectromet lc/m lc/ms/m system use rang applic complex proteom analys routin industri qualiti assur qualiti control qa/qc ion chromatographi ic separ ionic charg highli polar molecul sugar carbohydr usual found water-bas solut typic detect base electr conduct ic product use wide rang applic includ scientif research environment test well qualiti control pharmaceut food beverag industri process ga chromatographi gc analyz complex sampl matric gass compris separ detect technology- separ technolog common ga chromatographi analyz pair either convent detector gc differ type mass spectromet gc/m gc/m offer includ tripl stage quadrupol singl stage quadrupol orbitrap ion trap rang applic includ food safeti test quantit screen environment sampl complex molecular analys element analysi use atom spectroscopi techniqu identifi trace concentr element liquid solid sampl primarili environment petrochem foodspectromet safeti metallurg geochem clinical/toxicolog research applic product wide use growth market china india latin america support complianc increasingli stringent intern environment consum safeti regul mariu zoican univers toronto rotman school manag januari
chemic analysi tmo chemic analysi busi sell varieti instrument help
custom quickli analyz chemic make-up materi improv effici measur
substanc ensur complianc regul industri safeti standard chemic
analysi busi broadli split four categori miner materi instrument
portabl instrument radiat measur secur product environment
process instrument complement instrument offer equip servic
calibr instrument management/train servic
figur overview chemic analysi offer
materi structur analysi follow acquisit fei septemb
billion ltm sale leader electron microscopi creat materi
structur analysi busi unit overal fei ad million annual sale
grow low-single-digit rang time acquisit cryo-em technolog
still broadli earli stage adopt also time acquisit fei
custom base consist primarili appli market custom includ ga compani
manufactur semiconductor data storag equip well government
leverag leadership life scienc market util
commerci reach acceler cyro-em adopt integr structur biolog
thermo fisher mass spectrometri product offerings- tripl quadrupol system provid high perform quantit analysi chemic biolog fluid environment sampl food matric also use pharmaceut industri target quantit drug discoveri orbitrap provid high resolut accur mass capabl research appli market well suit drug metabol proteom environment analysi food safeti toxicolog clinic research applic also offer comprehens portfolio instrument control data analysi softwar help custom simplifi workflow ontain knowledg often complex data isotop ratio mass multi-collector isotop ratio induct coupl plasma high resolut trace mass spectrometri irm mass spectrometri mc/irm mass spectrometri icp/m spectrometri hr trace/m life scienc mass spectrometersinorgan mass spectrometersproduct groupapplic markets- on-line instrument analyz bulk materi non-invas real time- gaug system measur total thick basi weight coat thick flat-sheet materials- on-line analyz inspect packag good physic contamin valid fill quantiti check miss parts- portabl element analyz use x-ray fluoresc xrf technolog identifi metal alloy scrap metal recycl qa/qc preciou metal analysi environment analysi lead screen rang consum products- portabl optic analyz util raman fourier transform infrar ftir near-infrar nir technolog use field first respond law enforc militari personnel need quickli accur identifi chemic explos critic safeti secur situat applic includ qa/qc pharmaceut product identif counterfeit drug monitor detect identifi specif form radiat nuclear power environment industri medic secur applic product use first-respond safeti secur situat worker safeti nuclear power industri markets- fix portabl instrument help custom protect peopl environ well compli govern regul industri safeti standard measur ambient air stack ga emissions- ambient particul monitor applic provid continu measur log real-tim concentr median particl size airborn dust smoke mist fume improv effici increas worker safetymateri miner instrumentsindustri food beverag pharmaceut portabl analyt instrumentsindustri healthcar govern pharmaceuticalradi measur secur productsgovern industrialenvironment process instrumentsindustri mariu zoican univers toronto rotman school manag januari
workflow connect cryo-em mass spectrometri transform fei busi
meaning faster grow busi forecast grow mid- high-
single-digit rang also captur million cost synergi expect follow
best practic prior integr appli ppi busi system model refer
tmo electron microscopi busi current offer transmiss electron microscop
provid imag character atom scale scan electron microscop
resolv featur nanomet length scale dualbeam focus ion beam-scan
electron microscop
sampl prepar character
nanoprototyp industri failur analysi electr failur analysi instrument
use root caus failur analysi qualiti control among other
use
note materi structur analysi unit also hous tmo molecular spectroscopi
laboratori element analysi offer laboratori element analysi instrument analyz
bulk materi metal cement miner petrochem industri util x-ray
fluoresc xrf x-ray diffract xrd arc spark optic emiss oe techniqu
meanwhil molecular spectroscopi instrument typic use laboratori identifi
verifi quantifi organ materi pharmaceut biotechnolog polym chemic
forens scienc offer four primari techniqu includ ftir raman nir
specialti diagnost sale
estim specialti diagnost sd segment contribut roughli consolid
revenu offer broad portfolio diagnost product includ test kit
reagent cultur media instrument product use healthcar clinic
pharmaceut industri food safeti laboratori
expect sd segment sale fall report basi growth mute
divestitur anatom patholog busi complet longer term expect
sale grow compound-annual-growth-rate larg support rise demand diagnost
mean combat clinic challeng allergi infecti diseas heighten
regul regard food safeti overal util diagnost curtail rise global
healthcar cost note specialti diagnost segment tmo second highest margin
segment ebitda margin compani averag recent year
profit impact invest innov cascadion regulatori
figur sd revenu mix product type
diagnosticsconsolid ebit mariu zoican univers toronto rotman school manag januari
establish sd unit follow acquisit brahm million
sale septemb ad vitro diagnost test variou infect
diseas brahm biomark test measur pct level assess infect sever
identifi ill point care pct test help identifi patient would benefit
antibiot also use facilit target antibiot util mitig
resist brahm develop assay compat equip roch samsung
abbott siemen healthin major diagnost equip manufactur
today acceler brahm top-line growth rate grow
compound-annual-growth-rate sinc acquisit brahm oper margin also improv pt
leverag ppi channel relationship
figur brahm revenu growth million acquisit in-vitro
follow brahm acquisit august acquir phadia billion
sale bolster offer allergi autoimmun test phadia sell
immunocap allergi elia autoimmun system laboratori around world
share allergi test global prior acquisit note time
acquisit phadia boast impress oper margin septemb
ad transplant diagnost capabl specialti diagnost segment acquir
one lambda million sale despit play rel smaller market one
lambda held market share time acquisit custom grow
entranc specialti diagnost arena past decad help
diversifi compani away outsiz exposur academic/govern biopharma
end market provid access highli visibl higher margin diagnost market
tend greater opportun price power leverag importantli sd divid
anatom patholog healthcar market channel note agre sell
anatom patholog busi phc hold corpor privat billion
sale januari deal close end
mariu zoican univers toronto rotman school manag januari
figur sd revenu mix busi
clinic diagnost tmo clinic diagnost busi market analyz reagent
analysi measur blood urin chemistri glucos cholesterol
assess advanc test certain protein therapeut drug monitor drug
abus test oem busi manufactur label well privat label
compani
also build clinic mass spectrometri busi april announc fda
approv alti quanti mass spectromet class devic recent
conduct limit commerci launch europ cascadion analyz current
run vitamin assay albeit acknowledg expect expand test menu time
histor sophist rigor train user abl util mass
spectrometri year sought creat mass spectrometri instrument
use typic medic technician note cascadion analyz
meaning contribut top-line manag expect sale ramp time
immunodiagnost tmo immunodiagnost busi offer system support
diagnosi monitor allergi asthma autoimmun diseas tmo phadia brand
offer allergi assay cover peanut dander pollen bee venom among other
phadia blood test help practition better assess degre sensit specif allergi
enabl better commun patient sever potenti reaction importantli
calcul kilounot allergen-specif immunoglobulin antibodi per liter test
precis detect allergi symptom develop test also explain
progress allerg reaction
moreov offer preclin test procalcitonin pct pct indic sepsi
test allow practition provid prevent care patient show symptom
pct test also use detect neonat sepsi lower respiratori tract infect
acut heart failur well facilit judici util antibiot note
accord cdc one three antibiot prescript unnecessari contribut
rise human resist antibiot
transplant diagnost transplant diagnost enabl transplant center hospit
evalu compat donor recipi pre-transpl well detect antibodi
lead transplant reject tmo transplant diagnost busi bring togeth life
scienc tool dna sequenc human leukocyt antigen hla assay data
scienc capabl transplant clinic research
microbiolog microbiolog busi sell varieti lab product includ cultur media
collect transport system instrument consum detect pathogen
blood qualiti control product product aid diagnosi infecti diseas
healthcar market mariu zoican univers toronto rotman school manag januari
determin antimicrobi therapi detect contamin manufactur
facil tmo microbiolog busi also offer product safeti test food
pharmaceut anim health industri
clinic diagnost manufactur well third parti cover wide varieti
consum diagnost kit equip servic hospit physician clinic
refer lab clinic test facil ad busi portfolio
part merger fisher scientif
fisher scientif channel serv one-stop-shop custom
provid access one million laboratori product span equip associ
consum enabl streamlin research sourc one vendor furthermor
tmo self-manufactur product offer innov best-in-class solut optim drug
develop discov product importantli breadth channel busi
allow present step biopharma custom workflow everi
corner budgetari spectrum
due breadth product servic portfolio subject wide varieti
competitor across lab product life scienc analyt instrument diagnost
figur largest life scienc tool player billion
figur organ growth rate life scienc tool diagnost peer group billion
germany-bas merck kga scienc technolog compani gener billion
revenu report growth stem healthcar sale life
scienc perform materi mrk de healthcar busi
fishermerck kgadanah becton dickinsonavantaragilentmettler-toledoperkin mariu zoican univers toronto rotman school manag
manufactur drug sell comprehens diagnost solut high-precis effect
allergi treatment life scienc mrk de offer chemic equip academ lab
biopharma manufactur addit industri compani mrk de acquir sigma
aldrich novemb billion ad billion annual life scienc revenu
portfolio mrk de bioprocess busi compet bio-continuum
platform launch provid continu bioprocess servic manufactur
monoclon antibodi mrk de perform materi segment manufactur specialti
chemic suppli provid solut display comput chip surfac
design manufactur market product servic profession medic
industri commerci use sale support strong brand name major market
posit innov technolog gener billion revenu four
busi unit life scienc sale diagnost environment appli
solut dental note ipo- dental busi
septemb recent complet exchang offer complet divestitur
busi
dhr life scienc platform compet sever area includ ab
sciex mass spectrometri leica microsystemss microscopi busi like
util razor/razor blade model greater consum focu revenu
moreov dhr recent pend acquisit biopharma billion
announc februari ad billion bioprocess revenu
significantli enhanc presenc chromatographi single-us technolog cell cultur
media note typic allow acquir entiti remain autonom wherebi
broadli keep acquir oper compani separ compar
fulli integr busi unifi offer
medic technolog compani gener billion
revenu medic life scienc intervent busi life scienc
segment gener billion revenu includ preanalyt system
diagnost system bioscienc divis note previous octob
sold advanc bioprocess busi million
preanalyt system busi offer integr system specimen collect addit
safety-engin blood collect product system diagnost system busi
sell autom blood cultur molecular test system rapid assay microorgan
drug suscept system meanwhil bioprocess busi compet
cell analysi kit reagent system bench-sid solut single-cel gene express
lead global manufactur distributor product servic
custom locat across countri like lever
govern agenc well manufactur util advanc technolog appli
materi avtr offer typic use function well product process
goal support custom develop new innov product lower
develop product cost improv product process perform characterist
enhanc safeti reliabl drug devic product
grew meaning novemb acquisit vwr intern global
manufactur distributor laboratori product product servic transact
result revenu ebitda increas respect combin
entiti may complet ipo began trade nyse
mariu zoican univers toronto rotman school manag
agil global player life scienc diagnost revenu billion
agil life scienc appli market segment revenu sell product
instrument use applic liquid chromatographi ga chromatographi mass
spectrometri spectroscopi softwar informat lab autom robot vacuum
technolog cell analysi diagnost genom segment revenu
gener revenu product support applic patholog specif protein
flow reagent companion diagnost target enrich cytogenet research solut
microarray pcr qpcr instrument molecular biolog reagent nucleic acid
solut autom electrophoresi microfluid remain agil
revenu sourc crosslab busi suppli chemistri consum
servic support major end-market varieti third-parti vendor
compet tmo research safeti market channel busi
post billion revenu product servic
approxim revenu gener sale laboratori servic
instrument laboratori balanc liquid pipet solut autom lab reactor
titrat spectrophotomet moistur analyz product varieti custom
includ pharmaceut biotechnolog compani approxim sale
sourc industri servic instrument sold custom pharmaceut
chemic food discret manufactur industri
gener billion revenu includ discoveri analyt
solut segment serv life scienc appli market
diagnost segment offer reagent informat detect imag technolog
life scienc custom includ pharmaceut biotechnolog compani addit
academ institut appli market provid analyt technolog
servic environment food industri custom assist food environment
qualiti test diagnost segment sell instrument reagent assay platform
softwar clinician medic research institut emphasi
product support reproduct health emerg market diagnost appli genom
includ earli detect genet disord
compet liquid chromatographi mass spectrometri record
billion revenu busi made two segment water
revenu ta water product market segment primari offer
high performance/ultra perform liquid chromatographi mass spectrometers/lcm
accessori chromatographi column usabl wat-brand third
analysi rheometri calorimet note wat custom mix skew toward
pharmaceut account account revenu versu industri
gener billion revenu bruker scientif instrument
segment includ biospin calid chemic appli market life scienc
vitro diagnost detect busi biospin segment manufactur
distribut life scienc tool base magnet reson technolog academ
government custom calid segment manufactur distribut wide varieti
product pharmaceut biotechnolog diagnost compani addit academ
institut hospit govern forens lab food beverag lab
mariu zoican univers toronto rotman school manag
establish leader life scienc tool diagnost industri
global scale commerci logist reach diversifi product servic
offer leverag size scale provid wide rang instrument
consum servic research scientist across varieti industri
benefit healthi industri fundament end-market near
rise healthcar cost associ age popul grow demand
treatment complex chronic diseas underpin secular trend current fuel
invest healthcar servic infrastructur research global accord
evaluatepharma global pharmaceut spend expect rise billion
see figur coincid rise us nation healthcar expenditur increas
compound-annual-growth-rate figur structur tailwind continu drive
greater demand diagnost novel biolog therapi address world
complex oner diseas threat cancer alzheim arthriti diabet heart
diseas simultan discrep standard environment manag
food safeti across nation narrow emerg market introduc regul
confront concern food drug safeti pollut
figur histor project global spend bln
evaluatepharma world preview outlook credit suiss
healthi fundament backdrop well-posit captur increment market share
given increasingli comprehens offer one-stop shop life scienc tool
space magnifi extens suppli chain presenc govern academ institut
corpor look curtail budgetari restrict consolid spend tmo
wide-rang product offer instrument consum relev technolog
allow compani servic broad array custom across entir workflow
establish rel sticki custom relationship process
tmo portfolio support extens fisher scientif suppli chain popular e-commerc
busi via thermofish com fishersci com corpor account program
servic strateg custom c-suit relationship corpor account
team sell product four primari busi segment custom four end
market simplifi cross-sel opportun importantli access wide set custom
enabl track puls varieti industri well collabor expert
innov identifi new technolog applic better meet custom need
mariu zoican univers toronto rotman school manag januari
figur escal us nation healthcar expenditur bln
center medicar medicaid servic credit suiss
view diversifi platform competit advantag particularli given inher
fluctuat dynam biopharma healthcar academic/govern industri
end market divers set end market help provid hedg natur downturn
track multipl data point measur health biotech fund environ
accord bioworld comprehens data sourc biotech fund includ public
privat sourc increas decemb sequenti deterior growth
novemb figur figur overal biotech fund fell heel
jump said absolut fund level remain robust overal point
sustain health across fund landscap caveat emphas fund
stem multipl sourc may fulli repres data instanc larg
pharmaceut compani repres key sourc fund small mid-siz
biotech compani inher insul broader capit market activ
ventur capit public market fund
figur quarterli overal biotech fund incl public offer fund public biotechnolog compani fund
privat biotechnolog compani
public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant debt
offer right offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat firm
biotechspublic/otherpubl growth mariu zoican univers toronto rotman school manag januari
figur monthli overal biotech fund incl public offer fund public biotechnolog compani fund
privat biotechnolog compani
public offer includ ipo follow-on public/oth includ financ public compani includ loan bridg financ exercis warrant debt
offer right offer standard privat placement pipe financ institut offer regist stock privat biotech includ financ privat firm
educ govern fund remain healthi
repres revenu govern fund across sever key countri
region includ unit state europ china often key area investor
focu time drive increment volatil specif domest govern fund
repres revenu organ nation scienc
foundat nation institut nih fund univers govern program
cooper agreement grant contract
follow robust nih fund increas billion support
rise us academ spend nih fund increas slightli moder rate
billion still better ten year compound-annual-growth-rate
budget bill support still overal healthi fund environ us
encourag recent nih fund appropri includ year-over-year
increas billion provid rel tailwind vs prior year importantli although
trump administr consist sought nih fund cut excess widespread
bipartisan congression support result signific annual increas nih fund
recent year trend expect continu go forward well
biotechspublic/otherpubl mariu zoican univers toronto rotman school manag januari
figur nation institut nih billion
note estim base senat spend panel draft spend
europ take closer look horizon program laid european union
parliament support academ commerci research across member state
contribut countri current program horizon includ billion
fund dedic research invest seven year eu
budget implement increas horizon program note
demograph chang well-being budget particular receiv boost
importantli april european union parliament announc next larg research
program known horizon europ run
billion fund offer near-term comfort stabil research scientist
worri impact eu parliamentari elect albeit potenti volatil
stem brexit mission area horizon europ includ adapt climat
chang cancer climate-neutr smart citi healthi ocean sea coastal inland
water soil health food said still await adopt horizon europ
packag occur follow eu parliament agreement next multiannu
financ framework mff remind eu broad-rang research program began
horizon europ program repres ninth segment seri
research fund associ program account eu member
govern spend total annual initi fund valu encourag note
program final continu seek updat
figur european union research develop fund program
offici journal european union sciencebusi net credit suiss estim euro billion
propos growth vs horizon europ mariu zoican univers toronto rotman school manag januari
histor govern fund dynam expos life scienc peer volatil
posit fund news drive increment upsid tighten budget drive potenti
downsid past year begun reduc exposur dynam
particularli follow acquisit patheon said note continu
rel expos govern educ fund closest peer figur
figur tmo govern educ fund
figur govern educ fund exposur
across life scienc peer group
maintain diversifi portfolio recent year made signific effort
increas penetr faster grow biopharma market organ invest
acquisit affymetrix fei patheon tmo increas focu
biopharma market inher faster end-market help continu achiev
surpass long-term organ growth goal view importantli extens
capabl allow provid comprehens end-to-end product offer solut across
biopharma workflow
self-manufactur product offer innov best-in-class solut optim drug
develop discoveri product support develop biolog single-us
technolog cell cultur media mass spectromet chromatographi platform
also provid tool across multipl workflow exampl meet need car-
workflow provid magnet separ technolog vector product system
t-cell media serum replac
note also tool provid offer four major genet test capabl
sanger sequenc qpcr microarray
includ platform assay
consum importantli tmo genet analysi platform connect thermo
fisher connect cloud enabl robust rapid analysi tmo vast relationship
pharmaceut biotech diagnost compani enabl deploy genet test
portfolio aid compani develop companion diagnost associ specif
drug develop
ttmpatheon acquir aug mariu zoican univers toronto rotman school manag
figur rise biopharma exposur sale
recent quarter biopharma custom base meaning driver organ
revenu growth grow mid-teen clip acceler rel hsd
growth approxim growth sale deriv
pharmaceut biotech custom increas ttm
ttm quarterli organ growth underli custom averag
momentum across biopharma end market continu fuel favor global
secular healthcar driver includ previous highlight factor age
demograph strong fund extern drug discoveri well rise
innov develop specialti medicin address challeng associ
chronic diseas overal matur sophist standard medic care
research develop life scienc market remain healthi varieti
sourc includ govern startup larg pharmaceut compani invest
roughli billion annual specif relat biopharma market accord
preclin research leader charl river laboratori small mid-siz biopharma
compani grow faster top global biopharmaceut compani key
growth driver support emerg compani burgeon
develop pipelin proprietari instrument product well
channel busi broader servic solut biotech compani continu play
increasingli import role drug develop continuum innov engin
less total pipelin attribut top biopharma accord
iqvia institut given biotech increas ownership global pipelin industri
unsurprisingli larger better fund decad ago includ compani
ttmpatheon acquir aug sep market biotech hsd hsd msd hsd msd mdd ldd mdd hsd hsd ldd ldddiagnostics/healthcareflat msd msd msd lsd lsd lsd msd msd msd msd lsdacademic/governmentsoft lsd lsd hsd-lsd lsd lsd msd lsd lsd lsd lsdapplied/industri msd lsd msd msd lsd lsd lsd lsd lsd lsd-lsd lsdend market mariu zoican univers toronto rotman school manag januari
figur percentag late-stag pipelin compani size emerg biopharma
support aforement healthi fund dynam innov research singl
cell proteom analysi spur introduct novel therapeut grow focu
person medicin target therapi improv overal valu health
outcom term approv larg molecul drug approv us
food drug administr fda repres total approv new high water
mark industri figur biolog drug approv see
increas divers biolog mab repres roughli approv larg
molecul drug rprotein rna therapeut
also highlight next-gener ngb cell gene nucleotid
therapi account overal pipelin accord iqvia institut
doubl number sinc reach compound end vs
acknowledg drug class rel infanc though late-
state ngb pipelin phase ii develop moreov three ngb launch
bring total number ngb market
figur fda approv larg molecul
avantor drug administr
avantor drug administr
moleculelarg moleculemab mariu zoican univers toronto rotman school manag januari
new larg molecul drug come market biolog continu repres grow
portion effort product larg molecul sale continu grow
healthi clip accord evaluatepharma biolog sale grown compound-annual-growth-rate
expect grow compound-annual-growth-rate repres nearli
billion sale figur
figur biolog drug sale billion
meaning growth biolog sale continu manufactur focu
develop complex drug larg molecul drug price reflect costli
natur develop process accord evaluatepharma biolog spend increas
percentag overal spend pharmaceut long term rise
shift mind biopharma compani priorit larg molecul
project view tmo growth strategi well-align favor market dynam
expand overal focu biopharma end market
figur world-wide prescript sale biolog rise proport spend
evaluatepharma world preview outlook credit suiss estim
howev despit rise overal demand biolog oner regulatori backdrop drug
price reimburs pressur rise threat generic/biosimilar disrupt
overal rise cost complianc amongst factor led profit deterior
across biopharmaceut industri mean combat margin compress
biolog spend totalestim convent drug spend estim spend mariu zoican univers toronto rotman school manag januari
biopharmaceut compani develop highli complex costli therapeut
immuno-oncolog treatment seek expedit time-to-market potenti candid
also ensur innov qualiti control efficaci
figur weaker econom larg cap pharma
figur irr larg cap pharma
deloitt credit suiss million
deloitt credit suiss estim measur deloitt estim
drug sale divid invest
given conflict pressur well-posit capit evolv role
larg molecul therapeut address global health concern help custom across
entir biopharma workflow achiev greater effici act one-stop-
shop fisher scientif channel provid easi access one million laboratori
product across numer workflow also recent increas clinic trial logist
busi also help custom address aforement challeng drug
develop grow contract develop manufactur busi
remind first enter market acquisit patheon second largest
global august importantli current expand patheon st loui
plant million project complet facil largest outsourc
single-us biolog site north america
may acquir brammer lead viral vector develop
manufactur view brammer acquisit particularli meaning
manufactur vector requir gene therapi often cost prohibit make
util cdmo inher attract gene therapi drug applic prolifer
across develop continuum new submiss expect
approv annual accord fda buoy new deliveri method
includ viral vector experi substanti return billion invest
brammer view year-end clinic trial on-going global
relat regen medicin target enrol patient figur
support long term mega trend
bring assetto marketforecast peak salesp mariu zoican univers toronto rotman school manag januari
therapi end
allianc regen medicin credit suiss estim
industry-lead billion annual budget manufactur revenu
 scientists/engin commit deliv high-impact innov
custom across segment innov driven customer-centr
focu vast scale enabl collect inform collabor custom key
opinion leader identifi need potenti new approach note appear
lag rel larger diversifi peer spend percentag sale figur
note roughli in-lin margin ahead peer isol
manufactur revenu revenu channel servic busi may obscur
figur spend manufactur revenu
segment
figur spend compani
compani data credit suiss estim million
sinc also reli scientif advisori board compris world-renown
scientif expert order commun import scientif inform trend
manag help keep finger industri puls provid invalu
feedback regard potenti impact pipelin project
therapygene-modifi celltherapycel therapytissu engineeringphas iphas iiphas mariu zoican univers toronto rotman school manag januari
support scientif advisori board broadli help inform tmo engin
tmo innov strategi hing four element
deliv best-in-class new product time develop lead
franchis number function area exampl tmo orbitrap mass spectromet
initi launch becom lead technolog provid high resolut
accur mass capabl varieti applic includ research drug
metabol proteom environment analysi food safeti toxicolog clinic
research addit part acquisit gain
access quantstudio franchis real-tim qpcr instrument integr digit
pcr qpcr upgrad platform introduc cloud-en
quant-studio qpcr system support tmo focu oncolog bolster
qpcr offer
leverag new product capabl advanc scientif discoveri
follow septemb acquisit fei gain access electron
microscopi market within coupl year turn fei low-single-digit
growth busi double-digit growth market larger custom base well
invest enhanc offer ultim drive greater adopt rate
across academ pharmaceut end market
migrat innov custom end market way exampl origin
target high-end research orbitrap use food safeti toxicolog
applic also work increas util mass spectromet clinic
util up-to-d digit tool tmo new instrument connect thermo
fisher cloud allow user access data remot importantli develop
remot instrument diagnost capabl algorithm sensor provid real-tim
inform use increas uptim maxim effici servic support
tmo innov process support consist product launch across
segment continu drive revenu growth longer term
memberexperi detailsdavid sabatinimemb whitehead institut biomed research biolog professor mitwilliam hahnmed oncologist professor dana-farb cancer instituteaviv regevcomput system biologist well professor biolog mitarnold levineprofessor emeritu system biolog institut advanc studi princetontyl jacksdirector mit koch institut integr cancer researchedison liudirector jackson laboratorystev gygiprofessor cell biolog harvardc martin harrisassoci vice presid health enterpris chief busi offic medic school univers texa austincynthia wolbergerstructur biologist john hopkin univers school medicinelaura sepp-lorenzinocurr vice-president head nucleic acid therapi vertex mariu zoican univers toronto rotman school manag januari
mark entranc faster grow annual highli fragment
under-penetrated contract develop manufactur organ space
altisanalyt instrumentstripl quadrupol mass quanti md mass spectrometeranalyt instrumentsfor use clinic diagnost md hplcanalyt instrumentschromatographi focu resolut vs instrumentscompact high resolut electron discoveri autom systemanalyt instrumentsconnect bioreactor control softwar easier data explori instrumentscombin mass spectrometri technolog intelligence-driven data eclips tribridanalyt instrumentshigh-perform mass spectromet improv multi-attribut methodanalyt instrumentshigh-resolut mass spectrometri instrumentsfirst electron diffract solut real-tim pcrlife scienc solutionssmart instrument includ voice-activ command hand free summit ftir spectrometeranalyt instrumentsmolecular spectroscopi design fro qa/qc teach dualbeamanalyt instruments beam scan electron test peanut allergiesspecialti diagnosticsfda clearanc blood cryo-temanalyt instrumentselectrong microscop life diagnostics autom benchtop system perform immunocap elia pharosanalyt instrumentsdesktop scan electron evo scienc solutionsdigit microscop cell em singl quadanalyt instrumentsmass spectromet high-volum lc-m exact uhmranalyt instrumentsexpand orbitrap platform -- hybrid quadrupol tribridanalyt instrumentssmal molecul scienc solutionsnex-gen sequenc kryptor goldspecialti diagnosticsautom immunoassay duo uhplcanalyt instrumentsliquid xtranalyt instrumentsaug chromatographi data instrumentsextrem high resolut electron microscop advanc semiconductor genestudio scienc solutionssemiconductor-bas next-gen sequenc mariu zoican univers toronto rotman school manag januari
acquisit patheon august billion ebitda sinc
busi key growth driver lp segment post
organ growth segment follow growth
respect go forward continu view unit support top-line growth particularli
continu expand presenc organ inorgan top player
compris total market dive deeper patheon acquisit
broader market opportun focu also expand presenc
recent acquisit brammer
market worth sizeabl billion current market penetr
manufactur outsourc impli billion market opportun industri
broadli dedic provid servic develop product prescript
over-the-counter pharmaceut product import servic includ pharmaceut develop
pd market opportun drug substanc develop drug product
dp drug substanc commerci dss highlight figur
power secular growth driver includ increasingli complex target pipelin
address grow global healthcar concern rise demand biolog gene/cel therapi
heighten regulatori scrutini reimburs risk mount profit pressur
biopharma compani help drive greater outsourc pharmaceut develop
manufactur process given aforement driver expect overal penetr
rise next five year current
pd drug substancedevelop dss drug product dp drug substanc commerci dss total global opportunitykey competitorspatheoncatalentaenovavetteraesicakey competitorspatheonlonzacambrexwuxi pharmatechcmc biologicsalbanymolecularsiegfriedboehringersamsungbiologicskey competitorspatheonsiegfriedwuxipharmatechalmaclonzakey competitorspatheoncapsugelaaipharmaalmaccatalentest mariu zoican univers toronto rotman school manag januari
figur import factor decid outsourc
figur import factor select contract
patheon grand entranc grow market
remind acquir patheon second largest global august
billion ebitda mark tmo entranc broader market
given aforement attract market fundament expect combin offer
patheon facilit distinct competit advantag opportun captur
greater wallet share amongst patheon core biopharma custom
potenti cross-sel opportun across biolog develop manufactur capabl
bioproduct technolog
compani data credit suiss estim million -patheon revenu ltm public compani
million
unlik competitor patheon exist end-to-end platform provid highli customiz
servic across product life-cycle earli compound develop
develop servic pd commerci manufactur drug product servic
dp shown figur broadli patheon offer comprehens rang activ
pharmaceut ingredi api finish drug product servic across small molecul
larg molecul product includ formul develop clinic commercial-scal
manufactur packag life cycl manag time acquisit client base
consist pharmaceut biotechnolog custom across countri
manufactur outsourc fda approv drug evid
lead posit superior end-to-end offer
lack focu busi servic fisherpathoenopportunity- cell cultur media- single-us technologies- control system software- clinic trial packaging- formul develop services- clnical trial distribution- clinic trial manufactur capability- clinic trial logist provider- biolog develop manufactur capabl expertisecr uniqu biolog develop manufactur capabilitybioproductionclin trialsenh abil acceler innov drive product drug devleop mariu zoican univers toronto rotman school manag januari
figur patheon breadth capabl
support bioproduct bioprocess offer legaci fisher clinic servic
clinic trial logist busi wide rang biopharma instrument consum
product combin entiti capabl servic biopharma custom
earliest stage research serv direct pipelin later servic
key pillar project million revenue-rel synergi million oper
figur tmo suit offer
brammer invest increment capabl
may acquir brammer viral vector manufactur gene cell
therapi billion sale brammer ad key capabl around
emerg technolog like gene cell therapi better posit market
captur emerg growth opportun brammer expect grow
rang mid-term
product life cyclepreclinicalearli clinic develop phi-iia late clinic develop phiib-iii commercialgeneric-biosimilardrug substanc servic small larg molecul dss rout select cell line developmentprocess developmentscal valid scmcommerci manufactur lcc sourcingsecond gener processpharmaceut develop servic pd pre-formulationformul developmentscal developmentgener process new formulationdrug product servic dp commerci manufacturinggener process new formul gener drug substanc drug product develop-mentclin trial mfrgclinic trial packag materi distribut logisticscommerci mfrg drug substanc drug productlifecycl mariu zoican univers toronto rotman school manag januari
figur evolut product revenu
figur number global cell- gene-technolog product time
citelin global cell gene therapi pipelin septemb lonza
arena
outsid larger highlight smaller invest organ inorgan aim
bolster tmo posit market figur invest
announc period throughout emphas manag continu focu
market expect endur go-forward basi
glaxosmithklin gsk cork facil acquisit gsk site cork
ireland complet begin expand activ
ingredi api network capac order support demand ad increment
employe api use treat diseas includ childhood cancer depress
parkinson term strateg rational note capac
util get fairli high two current api manufactur site linz austria
south carolina us determin acquir anoth state-of-the-art facil
would cost-effect build would cost
mammalian microbialproductsemerg technologiesoth iphas iiphas iiilaunch pre mariu zoican univers toronto rotman school manag januari
billion remind announc agreement acquir gsk api facil
million may
geograph expans focu market
expect sale emerg market particularli apac region contribut materi
tmo top-line growth forese futur growth market buoy rise
global healthcar spending/invest respons age popul challeng
chronic infecti diseas adopt rigor standard food
safeti environment regul across develop countri note appli market
includ food safeti environment test water qualiti repres estim
tmo emerg market revenu
figur histor organ growth rate geograph region
current present countri exist manufactur commerci
capabl high growth region china india south korea revenu
contribut emerg market expand significantli sinc rise
approxim billion revenu billion
notabl china repres approxim billion consolid sale vs
billion
investmentamount datedetailsinvest steril inject ad capac steril liquid freez dri product develop commerci manufactur specif expans includ two site itali one carolina acquisit gsk facil ireland gain access highli special api potenti treat childhood cancer depress parkinson st loui facil complet decemb expand st loui biolog facil legaci patheon hous project began make site largest outsourc single-us biolog site north america geograph america-lsd msd msd hsd lsd msd msd msd msd lsd lsd lsdeurop msd msd hsd msd-lsd msd msd hsd msd lsd lsd msdapac hsd lsd lsd lsd msd hsd hsd ldd hsd ldd ldd lddchina lddflat lsd msd hsd mdd mdd hdd mdd mdd hdd-row lsd-lsd-lsdflat lsd lsd-msd-hsd-hsd-msd-lsd-lsdgeograph america lsd msd lsd hsd lsd msd hsd hsd msd msd msdeurop msd lsd msd msd msd hsd hsd hsd msd msd hsdapac- hsd ldd ldd mdd ldd ldd ldd dd hsd hsdchina hdd mdd hdd hdd hdd strong strong mariu zoican univers toronto rotman school manag januari
figur emerg market revenu geographi
total revenu
expand sale exposur emerg market coincid rise gross domest
spend world-wide growth expenditur emerg market far
outpac growth develop nation unit state unit kingdom
organ econom co-oper develop oecd credit suiss
asiasouth korealatin americaeastern europemiddl asia korea america europ africa koreacosta mariu zoican univers toronto rotman school manag januari
order captur emerg market growth opportun made sever notabl
invest across region countri includ china lithuania singapor south korea
india among other particular emphasi life scienc market note key
invest figur
figur notabl invest emerg market
compani data credit suiss estim -more specif locat disclos -open life
technolog acquir
china remain key growth opportun also illustr tmo success thu far
emerg market countri tmo second largest geograph region
sale vs us averag organ growth growth
acceler given tmo meaning growth china expand
overal exposur countri becom increas area focu investor
increasingli scrutin govern invest develop agenda
major fund typic deriv public sector vs privat
statesjapangermanychinasouth koreafranceswitzerlandunit kingdomnetherlandstaiwanirelandswedenfinlandavg expens cagrr expens functionlocationyear openedbiosci custom explor centershanghai center expans suzhou china design centershanghai center experi centerdubai center center suzhou china center singapor centerseoul south center centershanghai mariu zoican univers toronto rotman school manag januari
figur histor china revenu million
figur exposur china revenu across life
encouragingli life scienc industri well align chines govern
prioriti outlin china five-year creat sever opportun relev
constitu histor medium-term plan focus agricultur develop
industri infrastructur econom develop recent initi
still remain focu china countri increasingli invest innov well
sustain develop includ heighten focu environ social well-b
offer tailwind life scienc constitu exampl constitu experienc growth
bolu follow target surfac water initi china drive mid-teen growth
life scienc compani
china thirteenth five-year plan support acceler growth life scienc tool
compani continu view focu increasingli shift next
year china fourteenth five-year next five-year plan focus
larg sustain develop increas emphasi also well-being qualiti
life view focu inevit stress scientif invest environment
health-rel innov continu offer enhanc growth opportun life scienc
constitu time
figur trajectori china year plan
specif highlight tmo strateg invest china exampl
open innov center shanghai enabl work local custom develop
launch market-specif product addit ad bioproduct
focusfirst scientif develop nation defensethird develop nation defensefourth develop industrializationfifth develop industrializationsixth develop industri nation defenseseventh develop develop scienc educationeighth developmentninth econom developmenttenth develop environmenteleventh develop environ public servicetwelfth infrastructur scientif innovationthirteenth environ healthcarefourteenth develop mariu zoican univers toronto rotman school manag
develop lab innov center introduc custom new technolog offer
local media cell cultur applic open precis medicin
center guangzhou establish custom train center beij
open bioprocess design center shanghai recent expand clinic trial
capabl suzhou facil becom tmo third largest clinic trial logist facil
china
invest support effort closer custom local
strategi allow better address custom need optim market
posit longer term also maintain strateg partnership emerg market
particular focu relationship chines govern pharmaceut compani
china wuxi also recent sign long-term partnership agreement
oem precis medicin segment
aforement invest collabor market also highlight
expand e-commerc infrastructur china grow china e-commerc
revenu million trend expect continu
contribut growth longer term expect continu penetr chines market
key compon tmo long term organ growth plan
detail focu area emerg market
south korea rise clinic trial demand south korea strong growth driver
tmo biopharma servic lp segment almost world biosimilar
product take place south korea industri side capit
strong semiconductor industri south korea engag compani like samsung
co-develop electron microscop furthermor countri healthi government
fund market-friendli regul extens healthcar servic clinic trial center
access patient popul contribut growth region recent
year continu tailwind futur well
india india pharmaceut industri hold lead posit manufactur
genet market expect capit longer term order support
industri india tomo establish clinic pack facil open india
chromatographi center excel also note signific growth opportun
contract research organ contract manufactur organ
cmo custom india moreov benefit govern invest
particularli india expand focu health safeti open food test
applic lab new delhi cooper indian govern
opportun emphas continu growth opportun appli
environment end market fuel converg global standard
regul food safeti environment control across develop market
tmo effort grow ep support commit drive effici
expand margin via practic process improv ppi busi system
product program synergi captur relat extens capit deploy strategi
detail page first introduc well-known oper effici framework
ppi sinc debut ppi becom key pillar strategi long term
profit improv part drive adjust oper margin
go forward expect continu experi margin expans despit
slight downtick compani move closer adjust oper margin
target shown figur
mariu zoican univers toronto rotman school manag januari
figur histor project annual adj oper margin
highlight key compon continu margin improv
practic process improv ppi busi system ppi focus enhanc
qualiti effici custom allegi mean acceler organ growth
increas profit grow cash flow industry-lead facilit
develop innov high qualiti product servic furthermor continu
improv tool includ lean kaizen help streamlin everyday
process remov wast ineffici busi model
consist disclos note kaizen event versu
also note ppi gener approxim million annual
save impress feat given size consolid busi
strateg product program also employ strateg product program
global sourc low-cost manufactur manufactur facil ration
mean improv long term profit global sourc look leverag
size scale optim consolid spend fewer supplier also
expand suppli chain low-cost region regard manufactur recent
year compani continu move volum low-cost manufactur region
demonstr grow number site china well acquir fei lithuanian
facil consolid manufactur facil
continu execut optim ration effort sinc
acquisition-rel deal synergi captur latent deal synergi recent
acquisit also help support margin expans time patheon acquir
august track achiev million acquisit synergi
million revenu contribut margin million cost synergi three year
post-clos note acquisition-rel margin improv may also driven
part ppi effort elimin redund public compani cost leverag
combin function support cost consolid manufactur footprint leverag
size scale optim suppli chain addit aforement invest
expand capac st loui plant steril fill/finish network drive
improv margin time
also note recent margin expans experi segment lss ai
experienc oper margin expans benefit oper
mariu zoican univers toronto rotman school manag
leverag driven strong organ growth howev specialti diagnost intern
invest regulatori area like continu suppress margin way
exampl one invest relat launch commerci
cascadion first immunoassay analyz use liquid chromatography/mass spectromet
capabl clinic set potenti drive height organ growth longer
term meanwhil lp patheon dilut relat invest push margin
downward lp histor tmo lowest margin busi owe larg part
natur suppli chain busi
importantli consolid basi tmo oper margin contract bp
dynam larg driven aforement dilut relat patheon
acquisit oper margin time acquisit well
unfavor mix almost fulli off-set ppi product higher volum note
patheon contribut basi point dilut howev
first full quarter lap patheon deal post oper margin
expans bp
figur ebit margin segment
return margin expans compani move closer
adjust oper margin target driven annual margin expans
organ top-line growth volum leverag price well continu benefit scale
tmo longer term capit deploy strategi assum alloc cash
strateg expect return sharehold via share buyback
dividend highlight tmo role consolid highli fragment life scienc
industri consist driven growth deliv valu strategi
dynam expect continu longer term also deliv valu sharehold
return billion capit sinc billion share buyback billion dividend
dividend relat outlay grown compound-annual-growth-rate sinc note futur
 share buyback current embed assumpt repres
upsid earn longer term
importantli expect pay million dividend yoy
alreadi repurchas million share regard net debt ttm ebitda
septemb ampl dri powder financ continu growth
scienc solutionsanalyt instrumentsspecialti diagnosticslaboratori product mariu zoican univers toronto rotman school manag januari
lead consolid highli fragment market proven track record
sinc complet transact billion includ billion
support ep growth averag focu bolt-on
transform acquisit rang acquisit
advanc bioprocess unit million add complementari cell cultur media
asset transform acquisit billion led
creation life scienc unit net leverag current ttm ebitda
expect remain activ consolid industri provid upsid
tmo acquisit strategi revolv around identifi opportun enhanc offer
custom improv strateg posit deliv sharehold return primarili
measur note chang hurdl rate sinc despit today
lower interest rate environ indic higher standard financi return
also keen limit acquisit view best owner target
compani highlight key transact figur
dividend mariu zoican univers toronto rotman school manag januari
term opportun market manag note pipelin deep four
oper segment potenti complet mid-to-larg size transact moreov
area focu like includ expans biopharma capabl specialti diagnost
cloud-bas technolog demonstr tmo recent acquisit finess solut
informat adjac similar affymetrix microarray system fei
electron microscopi leverag exist channel substanti commerci
capac creat meaning revenu synergi prior recent acquisit brammer
note activ dialogu pharmaceut compani cdmo regard
novemb bloomberg report consid bid leader
diagnost would repres one largest acquisit to-dat
potenti augment tmo recur revenu base also increas exposur test
product said announc decemb conclud
date announcedd completedtargetbusi segmentconsider million ev/sal viral vector gene therapi applic track record includ instrument softwar enhanc oper perform electron dickinson advanc bioprocess media supplement enhanc cell cultur media improv yield reduc variabl biopharmaceut dna platform use forens law enforc applic million annual sale presenc contract develop manufactur organ platform support genet analysi qpcr proteom control autom system softwar bioproduct transfect neurobiolog stem cell research perform electron america-bas provid cellular genet analysi manufactur research scientif single-us technolog custom bioprocess servic custom conduct scientif research genet analysi well appli vitro chain servic life scienc microelectron autoimmun diagnost systemssd -- microbiolog product sampl collect preserv ion scientificai lp -- laboratori chemic consum instrument cell biolog product genom chromatographi product proteom reagant element analysi in-vitro diagnost provid analyt instrument life scienc consum lab consum relat solut logist provid pharmaceut healthcar spectrophotometri flouresc scientif fine laboratori chemic sampl extract liquid instrument provid mass spectrometri instrument later divest two lead product gaug polym web gaug devic ma spectromet laboratori product rang lab equip use life sceinc drug discoveri clinic patashnick monitor instrument ambient air emiss monitor industri x-ray analyz metal petrochem environment inform managemnet system counsel servics asset manag mariu zoican univers toronto rotman school manag januari
review potenti strateg altern determin execut stand-alone busi
repres best opportun valu creation sharehold conjunct
determin manag termin discuss potenti acquir
tmo potenti acquisit tabl near term molecular diagnost next-gen
sequenc genom servic clearli repres area interest part
diversif strategi also provid pathway organ growth acceler
highlight manag develop impress integr track record
consist achiev revenu synergi cost save line ahead plan
detail recent achiev integr fei affymetrix life technolog
three signific transact sinc
fei expand custom base acquir technolog acceler growth
septemb acquir fei leader electron microscopi billion
sale repres third largest acquisit compani histori ad
million annual sale portfolio time acquisit fei custom base
weight heavili toward appli market custom includ manufactur
semiconductor data storag equip well oil ga compani
governmental/academ end market univers public/priv research
captur million total synergi includ million relat cost save
million oper incom accret revenue-rel synergi within three year
relat cost synergi elimin redund public compani cost leverag
global scale captur ppi-driven effici addit leverag complementari
product improv custom lead time expand biopharma base
enhanc fei annual revenu growth low-single-digit transact
double-digit
acquir fei bolster core legaci thermo electron instrument portfolio
first signific instrumentation-focus acquisit sinc acquir dionex billion
may fei provid access electron microscopi market nice
complement mass spectrometri chromatographi offer within tmo analyt
instrument segment attribut signific portion revenu synergi
achiev improv market fei product broader custom base mainli
expand offer life scienc custom
pre-acquisitionpost acquisit lsd/ msd msd/ hsdapplicationcapabilitiessynergi mass spectrometri asset enabl user analyz measur protein fei electron microscopi system cryo-em enabl user character analyz protein structur function spectroscopi element analysi portfolio enabl precis analysi bulk materi metal cement miner petrochem industriesfei scan transmiss electron microscop nano-characterizi use develop qualiti assur semiconductor nanotechnologiescost savingselimin public compani cost leverag global infrastructur ppi deployment- acceler life scienc penetr geograph expans fei asset chinarevenu synergi life sciences- combin molecular spectroscopi element analysi legaci fei materi sciencesrevenu synergi materi mariu zoican univers toronto rotman school manag januari
figur fei revenu mix geographi
figur fei revenu mix product
compani data credit suiss estim base revenu
compani data credit suiss estim base revenu
specif fei innov titan krio cryo-transmiss electron microscop cryo-em
natur extens flagship orbitrap mass spectrometri line biopharma custom
use structur biologist explor mechan compon biolog molecul cryo-
em use beam electron creat atomic-resolut imag frozen-hydr biolog
specimen cryogen temperatur high-growth instrument quickli disrupt lab
previous util x-ray crystallographi cryo-em technolog becom increasingli attract
biotech pharmaceut custom engag protein analysi develop
small larg molecular therapi research gener carri via use mass
spectromet particular cryo-em provid high resolut imageri highli preserv
biolog materi allow research observ function molecular interact
potenti drug candid develop process three scientist nobel
prize chemistri develop cryo-em high-resolut structur
determin biomolecul solut use titan krio
fei electron microscopi also mani use outsid life scienc particularli
materi scienc semiconductor industri gener growth end market
support new engin materi increas relianc nanotechnolog
grow complex architectur semiconductor addit expect fei continu
benefit decis china govern invest billion grow local
affymetrix fill tmo product suit
complet acquisit affymetrix march total purchas price
billion repres ev/sal ev/ebitda multipl respect
million million sale ebitda respect time purchas
affymetrix leader reproduct health agricultur bioscienc wide-rang
portfolio antibodi multiplex rna protein single-cel assay serv flow cytometri
market segment applic single-cel biolog immunotherapi infecti diseas
research notabl affymetrix busi recur natur time
acquisit strengthen life scienc segment consum mix
apac mariu zoican univers toronto rotman school manag januari
figur affymetrix revenu mix geographi
figur affymetrix revenu mix product
compani data credit suiss estim base affymetrix
compani data credit suiss estim base affymetrix
affymetrix ebiosci million revenu busi complement tmo
legaci bioscienc busi help gener strong growth sinc deal close three
year specif ebiosci portfolio reagent antibodi combin
attun nxt flow cytomet provid full-suit offer across flow
addit affymetrix held lead posit microarray applic alongsid agil
instrument commonli use genotyp gene express analysi
protein analysi recent innov genet test drastic drive cost
dna sequenc expect newli found access drive demand
gain market share long term leverag competit advantag
provid four major technolog prior acquisit offer three four
major genet scienc technolog includ domin posit qpcr real-tim pcr
sanger sequenc hold second posit next-gener sequenc
behind affymetrix microarray platform fill last gap genet scienc
offer allow compani servic heighten demand genom sequenc
clinic research molecular diagnost applic
affymetrix fit standard strategi take attract market opportun
lacklust margin leverag proven ppi busi system ambit
bolster acquir compani profit profil tmo averag experi
time acquisit plan includ oper effici stem ppi
also elimin former public compani cost manufactur site well
integr affymetrix exist commerci suppli chain opportun
better penetr apac market
mariu zoican univers toronto rotman school manag januari
figur captur million synergi affymetrix
tmo februari acquisit life technolog billion sale
transform life scienc offer rais consolid exposur recur consum
revenu six percentag point lead establish life scienc segment
obtain european regulatori approv divest cell cultur media sera gene
modul magnet bead sold ge healthcar billion januari
announc acquisit initi call million synergi compris
million revenu fall million cost synergi end
third year post-acquisit howev shortli deal close rais synergi level
million top-line synergi contribut margin million cost save
end exceed target achiev million cost synergi
notabl revenu synergi consist leverag life technolog e-commerc
strength support sale tmo lab consum chemic well sell life
technolog consum tmo larg corpor account synergi compris
elimin duplic public compani expens leverag combin scale ppi effort
consolid facil support function
far exceed synergi target also abl improv organ sale
legaci life technolog busi greater recent lss
segment post four consecut quarter high-single-digit growth greater
incom contribut revenu mariu zoican univers toronto rotman school manag januari
organ growth lss current mariu zoican univers toronto rotman school manag januari
earn outlook financi resourc
recap consolid revenu rose billion organ revenu growth
 a/divestitur fx robust organ growth led strength
life scienc solut specialti diagnost laboratori product
 servic partial off-set slower growth analyt instrument
geograph achiev high-single-digit organ top-line growth across europ china
incl china partial off-set north america mid-single-digit rest
world low-single-digit custom end market pharma led way
double-digit growth eight consecut quarter double-digit growth follow
diagnost healthcar high-single-digit academ govern mid-single-digit
appli industri flat gross margin contract bp reduct sg
percentag revenu offset bp drive oper margin
expans bp ep rose
conjunct earn print updat guidanc rais revenu
rang million vs previou ep
rang
forecast forecast revenu grew organ growth
billion driven strong core growth life scienc solut laboratori
product servic modest growth specialti diagnost
analyt instrument acquisit includ becton dickinson advanc
bioprocess busi acquir octob integenx acquir march
brammer expect add report top-line growth partial off-set
divestitur anatom patholog busi expect note top-line
also face difficult yoy comparison particularli segment
due broad-bas strength
forecast fx headwind bp top-line adjust oper margin
expand bp driven oper leverag on-going implement company-
wide ppi initi partial off-set fx headwind intern invest overal
ep increas
forecast forecast revenu grow organ growth
billion driven continu strength across life scienc solut core
laboratori product servic core less meaning growth analyt
instrument specialti diagnost core organ basi estim
residu contribut acquisit announc to-dat includ brammer
cork api manufactur facil add top-line growth partial off-set
divestitur anatom patholog busi expect expect
adjust oper margin expand bp driven oper leverag on-going
implement company-wid ppi initi synergi captur larger recent
acquisit net/net ep increas
long-term outlook longer term target annual organ growth
bp annual underli margin expans addit bp margin accret
acquisit half underli oper margin expans stem ppi
program half volum leverag price gain vari
year year expect annual convers drive signific capit deploy
includ dividend share repurchas
mariu zoican univers toronto rotman school manag januari
billion cash reserv billion debt net debt ebitda
capit deploy prioriti focus near term despit billion acquisit
brammer close may larg off-set sale anatom patholog
busi billion estim gener billion billion cash
flow oper respect
cash convers cycl current stand day inventori day
day notabl improv day decemb told forecast
call free cash flow billion enough financ
invest debt paydown steadi dividend current dividend yield
compani data credit suiss estim million
twelv monthsdaterevenuescogsinventoryreceivablespayablesrevenuescogsavg inven average aravg mariu zoican univers toronto rotman school manag januari
share current trade ebitda estim healthi premium
life scienc tool peer view valuat dispar warrant given
robust organ growth profil expand margin profil upsid current valuat
level may limit share current price near perfect manag
impress beat expect ep basi time sinc
demonstr abil success manag street view perform also offer
risk even slight miss offer meaning downsid potenti inevit higher
said target price base price-to-earnings ev/ebitda multipl
ep ebitda respect reflect even greater premium peer
predic grow recur revenu stream healthi innov pipelin diversif
higher growth busi emerg market substanti runway profit margin
improv capit deploy opportun
factset compani data credit suiss estim price market
close
factset compani data credit suiss estim price market
close
blue sky scenario predic organ growth upper end
current lt target greater margin expans thereon support oper
leverag ppi initi
ev/ebitdahist avgtmo ev/ebitda histor averag ev/ebitdahist avgtmo ev/ebitda histor averag iu zoican univers toronto rotman school manag januari
share grey sky scenario predic organ growth lower end
current lt target predic slow fund growth
stringent regulatori environ particularli custom consolid continu compound
potenti slower expect margin expans
factset compani data credit suiss estim price market close
perspect life scienc valuat alreadi notabl elev reflect healthi fast-
grow underli fundament life scienc compani experienc increas
invest focu critic tool develop new therapeut
associ product life scienc compani histor trade lofti premium
broader pursuant life scienc figur
cspriceupsid dailyrevenu cy average cy average ebitda cy average cy price-to-earnings cy ev/ebitda cy dividendtickerratingtargetdownsidepricecap volume scienc fisher servicesiqvia river group ag corp mariu zoican univers toronto rotman school manag januari
factset compani data credit suiss estim price market close
part analysi
sum-of-th part sotp analysi discount cash flow tmo four
oper segment life scienc solut specialti diagnost
laboratori product servic life scienc solut ascrib weight
averag cost capit wacc termin growth rate impli per share valu
assum proport net debt across busi analyt instrument
ascrib wacc termin growth rate repres valu per share
specialti diagnost appli wacc termin valu impli per
share valu lastli laboratori product servic ascrib wacc
termin growth rate drive per share valu assumpt larg
consist industri constitu within sub-seg sotp impli
consolid valu per share overal wacc impli
price-to-earnings price-to-earnings average lst index average spxhistor averag histor averag averag mariu zoican univers toronto rotman school manag januari
figur part analysi
compani data credit suiss estim million except per share
oper incomelif scienc product oper rate wacclif scienc product pv valuetermin growthlif scienc product termin valuelif scienc product net share mariu zoican univers toronto rotman school manag
cut govern spend us feder budgetari debat like persist
repres consist overhang industri peer uncertainti futur
fund tradit earmark biomed research presid trump propos
decreas nih fund part white hous budget plan repres
third time sought cut fund nih propos
nih fund still widespread bipartisan support congress view discuss
around govern spend continu drive volatil
fluctuat slow manufactur spend broader slow
manufactur spend direct end custom includ biopharmaceut
biomateri diagnost electron aerospac defens research compani could
signific advers impact demand tmo product servic factor
impact custom budget includ need develop new product continu
avail government fund competit avail resourc
macroeconom downturn deterior market condit could pressur top-line sale
growth particularli advanc technolog appli market also stymi
healthcar invest government agenc biopharmaceut compani
neg develop potenti spur on-going polit risk slowdown overal
demand would pose meaning headwind tmo organ revenu growth trajectori
rise competit laboratori suppli recent consolid laboratori
equip consum space danaher/g biopharma merck kgaa/sigma-aldrich
avantor/vwr may facilit increasingli competit environ amongst top competitor
custom consolid consolid across biopharma healthcar industri impli
fewer custom account concentr purchas decis drive increas price
pressur tmo product larger impact merger acquisit
space includ bristol-my squibb recent acquisit celgen januari takeda
pharmaceut acquisit shire may johnson johnson acquisit
actelion januari trend expect continu biopharma compani aim
leverag scale gain expertis off-set pressur increasingli stringent
regulatori environ drug price paradigm
deal integr risk quit often integr multipl busi therefor
predispos risk cultur shock key employe resign potenti
dissynergi could harm trajectori target compani distract core oper
importantli track achiev revenu deal synergi goal recent major
acquisit affymetrix fei patheon howev would remiss acknowledg
integr patheon remain on-going may pose greater challeng
rel past acquisit given rel lack experi capit intens
natur market evidenc million invest intern invest
million steril liquid lyophil freeze-dri product develop million
cork site million st loui site
channel conflict given role largest supplier self-manufactur third-parti
laboratori equip consum fisher scientif channel largest
custom simultan oftentim signific competitor chang
competit dynam discontinu third-parti relationship may materi affect
even view entranc industri posit obstacl
may includ headwind bioproduct segment stem loss busi
current custom repres competitor follow close transact
event scenario highlight given aforement attract opportun
industri patheon growth potenti long term off-set
earli headwind relat competit note previous success
navig similar conflict interest particularli follow acquisit fisher scientif
mariu zoican univers toronto rotman school manag
provid attract channel servic third-parti supplier without cannib
misus products/misappropri data tmo product enabl research
conduct power scientif test captur uniqu data extrem valuabl
client other must therefor take step ensur client use product
intend fashion februari halt sale genet sequenc
xinjiang region china respons accus product use
chines govern surveil citizen similarli tmo laboratori inform system
client network must suffici secur ensur data stolen stolen data
gener tool could use unintend purpos could face backlash
consum busi client govern
inabl manag leverag may hamper capit deploy stori view on-going
deal-mak lead rel high leverag ratio signific integr
macroeconom hiccup could drive debt pay struggl liquid issu would
hamper futur capit deploy signific compon growth strategi
importantli strong recur revenu base continu strong free cash flow gener
help off-set risk
foreign currenc fluctuat inher natur hedg constantli
evolv global market expos currenc fluctuat signific portion
sale deriv oversea unfavor exchang rate dollar reduc revenu
cash flow caus instabl report result
acceler manufactur spend broader acceler
manufactur spend direct end custom includ biopharmaceut
biomateri diagnost electron aerospac defens research compani could
signific posit impact demand tmo product servic
continu macroeconom strength strengthen market condit could
acceler top-line sale growth although industri constitu character strength
biopharma sustain posit develop could offer meaning tailwind tmo
better expect deal integr success captur synergi beyond
previou target meaning ahead previous disclos timelin relat recent
support overal custom penetr averag vs top custom
offer anoth pathway acceler growth trajectori longer term
mariu zoican univers toronto rotman school manag januari
tmo manag team compris veteran relev life scienc diagnost
biopharma servic industri importantli sever key execut long tenur
fundament maintain compani ppi program addit
sever key execut past acquisit join conjunct relat
acquisit board director includ individu deep divers set execut
experi major corpor includ novo nordisk hp inc merril lynch te
positionagebiographymarc casperpresid chief execut ceo sinc octob previous presid analyt technolog prior join serv presid ceo kendro laboratori product well presid american divis dade behr inc mark stevensonevp life scienc evp presid life scienc solut follow acquisit serv presid formerli presid appli biosystem stephen williamsonsvp chief european oper sinc held variou financi leadership role name svp cfo formerli vice-president cfo apac frederick lowerysvp presid life scienc solut laboratori productsundisclosedjoin follow merger fisher scientif sinc serv svp presid laboratori product sinc presid laboratori product sinc previous serv vice-president gm life scienc research presid laboratori consum silvestersvp presid life scienc solutionsundisclosednam presid bioscienc follow acquisit assum current role serv presid emea lead integr invitogen appli biosystem daniel shinesvp presid serv svp presid sinc januari held variou manageri role sinc join recent presid chemic analysi presid chromatographi mass spectrometri patrick durbinsvp specialti presid specialti diagnost sinc join gener manag north america clinic servic serv presid biopharma servic formerli held variou manageri role covanc work year michael lagardesvp presid pharma join serv presid patheon sinc prior join patheon work manag director privat equiti partner fill varieti role philip electron includ ceo cfo domest applianc person north america divis gregori herremasvp presid custom svp presid also serv presid environment instrument svp presid presid bioscienc ladiwalasvp strategi corpor developmentundisclosedh join follow merger fisher scientif vice-president strategi busi develop previous work corpor develop fisher sinc begin career boxersvp gener counsel name svp gener counsel januari previous serv varieti busi legal role luxottica prior join luxottica attorney winston strawn mariu zoican univers toronto rotman school manag
figur quarterli ep million except per share amount
histor gener expens incom expens incom continu incom affiliate/minor incom avail common share gener expens incom avail gener expens incom avail mariu zoican univers toronto rotman school manag
figur quarterli revenu million except per share amount
histor scienc product scienc product scienc product impactlif scienc product impactlif scienc product revenu growthlif scienc product scienc product expenselif scienc product depreci incomelif scienc product oper mariu zoican univers toronto rotman school manag
figur annual ep million except per share amount
histor gener expens incom expens incom continu incom affiliates/minor incom avail common share gener expens incom avail gener expens incom avail mariu zoican univers toronto rotman school manag
figur annual revenu million except per share amount
histor scienc product scienc product scienc product impactlif scienc product impactlif scienc product revenu growth excl fxlife scienc product scienc product corpor depreci expenselif scienc product corpor depreci incomelif scienc product corpor oper mariu zoican univers toronto rotman school manag
figur histor project million
net incom continu defer incom gain sale stock-bas benefit stock-bas compens charg sale inventori revalu date non-cash expens cash provid use discontinu ni adjust retir cash provid continu net cash sale busi net cash sale sale increas restrict cash invest activ cash use invest proce issuanc long-term short-term compani common proce issuanc compani common proce issuanc compani common stock employe stock benefit stock-bas compens financ activ cash use financ rate effect decreas equival begn equival end flow net mariu zoican univers toronto rotman school manag
figur histor project balanc sheet million
sheet cash receiv less tax current current plant equip intang asset oblig current matur long-term payrol employe incom accru current incom long-term excess par comprehens sharehold liabil sharehold debt ltm mariu zoican univers toronto rotman school manag januari
peer global databas captur uniqu inform compani within credit
suiss coverag univers base relationship compani custom
supplier competitor databas built research analyst insight regard
relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag inform see novemb peer
mariu zoican univers toronto rotman school manag
compani mention price
labcorp america lh
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
